RSS
Links
-
Recent Posts
- (no title)
- Flu Challenge Studies at NIH
- Politics and Plagues
- OPERATION WHITECOAT
- You may hold the cure for the next epidemic
- National Security Implications of CRISPR-CAS9
- If Not Me, Then Who?
- JUMP START: ACCELERATING GOVERNMENT RESPONSE TO A NATIONAL BIOLOGICAL CRISIS
- The Reemergent 1977 H1N1 Strain and the Gain-of-Function Debate
- Ebola 2014: Pandemic Preparedness Lessons Learned
- Mitigating the Risks of Synthetic Biology
- Tracking Down Smallpox Before It Kills Anew
- Penn and Teller on the Anti-Vaccine Idiots
- Interview about WMD Center’s Report Card on Bio-Response
- John Snow Society Pump Handle Lecture Series 2013
Daily Archives: October 15, 2012
Interview with Luciana Borio
Luciana Borio, MD
Assistant Commissioner for Counterterrorism Policy and Director, Office of Counterterrorism and Emerging Threats in the Office of the Chief Scientist, US Food and Drug Administration
Description
In this interview, Dr. Borio outlines the evolving role that the Food Drug Administration (FDA) has assumed in the development of medical countermeasures. Under Dr. Borio’s leadership, the FDA has established the Medical Countermeasure Initiative (MCMi), which is an effort to hasten the development of these products, and to improve their odds of achieving FDA approval. The MCMi has made investments in improving the regulatory science that will be necessary for government’s ability to evaluate a new generation of medical products. Here, Dr. Borio discusses some of the successes that the FDA has achieved in this arena, such as the ability to evaluate and approve multiplex diagnostic assays, as well as the challenges that remain.
Video produced by the Center for Biosecurity of UPMC
Posted in Uncategorized
Leave a comment